Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 85

Sort by

Sort Order Select

Journal Articles

Outcome of bridging therapy in chimeric antigen receptor T cell treatment for Relapsed/Refractory B-cell non-Hodgkin lymphoma: A retrospective study.

Sanfang Tu, Langqi Wang, Shaojie Wu, Yanjie He, Chaoyang Song, Zhao Liang, Xuan Zhou, Lei Wang, Chunyan Yue, Lijuan Zhou, Jilong Yang, Yuhua Li

Blood (2025) 146 (Supplement 1): 8045.

https://doi.org/10.1182/blood-2025-8045

Published: 2025

Journal Articles

Wstf degradation through nuclear autophagy promotes inflammatory responses in primary myelofibrosis: Implications for XPO1 inhibitor-based therapeutic strategies

Na Xu, Ziyu Wen, Bingyu Lin, Jiayi Li, Xuan Zhou, Xiaoli Liu

Blood (2025) 146 (Supplement 1): 7280.

https://doi.org/10.1182/blood-2025-7280

Published: 2025

Journal Articles

Efficacy and safety of peginterferon alfa-2b for chronic myeloid leukemia and essential thrombocythemia during pregnancy

Ziyu Wen, Xuan Zhou, Bingyu Lin, Qiang WANG, Liping Ma, Huilan Zeng, Zhi Liu, Bolin He, Qing Zhang, Mei Zhong, Xiaoli Liu, Na Xu

Blood (2025) 146 (Supplement 1): 7358.

https://doi.org/10.1182/blood-2025-7358

Published: 2025

Journal Articles

Retrospective analysis of 30mg/kg ATLG in preventing GVHD after haploidentical hematopoietic stem cell transplantation

Sanfang Tu, Minhong Huang, Chaoyang Song, Yuxian Huang, Rui Huang, Yanjie He, Shaojie Wu, Xuan Zhou, Jilong Yang, Chunyan Yue, Lei Wang, Yuhua Li

Blood (2025) 146 (Supplement 1): 7754.

https://doi.org/10.1182/blood-2025-7754

Published: 2025

Journal Articles

Novel risk stratification of ph-like ALL cohort receiving CD19-directed CAR-T therapy

Cai Zihong, Bailin He, Baiwei Luo, Zhixiang Wang, Wenhao Zhong, Xuan Zhou, Qifa Liu, Peng Li, Yong-xian Hu, Jing PAN, Liang Huang, Hongsheng Zhou

Blood (2025) 146 (Supplement 1): 5108.

https://doi.org/10.1182/blood-2025-5108

Published: 2025

Journal Articles

Deeper remission achievement and longer leukemia-free survival with inati-cel as consolidation therapy in allogeneic transplant-ineligible adolescent and adult patients with B-ALL

Sanfang Tu, Kaixin Ou, Lei Wang, Xuan Zhou, Chaoyang Song, Shaojie Wu, Rui Huang, Yanjie He, Yuxian Huang, Chunyan Yue, Minhong Huang, Yuhua Li

Blood (2025) 146 (Supplement 1): 3353.

https://doi.org/10.1182/blood-2025-3353

Published: 2025

Journal Articles

Flumatinib versus nilotinib as first-line therapy for chronic myeloid leukemia in chronic Phase: A propensity score-matched cohort study

Ziyu Wen, Bingyu Lin, Qiang WANG, Xuan Zhou, Xiaoli Liu, Xin Du, Na Xu

Blood (2025) 146 (Supplement 1): 3776.

https://doi.org/10.1182/blood-2025-3776

Published: 2025

Journal Articles

Clinical study of single-center PDT-ALL-2016 regimen in the treatment of KMT2A-rearranged acute lymphoblastic leukemia

Jiaxin Zheng, Bailin He, Zhixiang Wang, Xuan Zhou, Wenhao Zhong, Qifa Liu, Hongsheng Zhou

Blood (2025) 146 (Supplement 1): 6866.

https://doi.org/10.1182/blood-2025-6866

Published: 2025

Journal Articles

Real-world efficacy of inaticabtagene autoleucel in adult B-cell acute lymphoblastic leukemia patients with high-risk molecular alterations

Blood (2025) 146 (Supplement 1): 6865.

https://doi.org/10.1182/blood-2025-6865

Published: 2025

Journal Articles

Neutrophil count is an independent prognostic indicator in early T-cell precursor lymphoblastic leukemia

Jieping Lin, Xiaoyuan Gong, Nanfang Zhuo, Chengming He, Yiming Cai, Zhixiang Wang, Xuan Zhou, Bailin He, Wenhao Zhong, Qifa Liu, Suning Chen, Yang Xu, Huafeng Wang, Ying Wang, Hongsheng Zhou

Blood (2025) 146 (Supplement 1): 6892.

https://doi.org/10.1182/blood-2025-6892

Published: 2025

Journal Articles

Updated Results from a Phase Ⅱ Clinical Trial：Safety and Efficacy of Azacitidine and Chidamide Maintenance after Allogeneic Hematopoietic Stem Cell Transplantation for Patients with High-Risk Acute Myeloid Leukemia

Chuting Yang, Rui Huang, Danian Nie, Yiqing Li, Yuming Zhang, Honghua He, Chaoyang Song, Sanfang Tu, Yaling Zheng, Xuan Zhou, Jie Chen, Hui Zeng, Yuhua Li

Blood (2024) 144 (Supplement 1): 1050.

https://doi.org/10.1182/blood-2024-201586

Published: 2024

Journal Articles

BEAT Chemofree Regimen for Relapsed/Refractory and De Novo T-ALL

Jieping Lin, Xuan Zhou, Zhixiang Wang, Dainan Lin, Yu Zhan, Zan Li, Jiwei Huang, Yonghua Li, Xudong Ma, Qifa Liu, Li Xuan, Yang Xu, Hongsheng Zhou

Blood (2024) 144 (Supplement 1): 5901.

https://doi.org/10.1182/blood-2024-203250

Published: 2024

Journal Articles

Demographic and Clinical Data in 118 Acquired Hemophilia a: Results from a Single Center Study

Hu Yingying, Xuan Zhou, Shuhua Li, Jing Sun, Jieyu Ye, Qifa Liu, Houmei Feng

Blood (2024) 144 (Supplement 1): 3979.

https://doi.org/10.1182/blood-2024-206976

Published: 2024

Journal Articles

Tucidinostat Plus Pediatric-Inspired Chemotherapy As First-Line Therapy for Newly Diagnosed ETP-ALL/Lbl: An Open-Label, Single-Arm, Phase 2 Trial

Jieping Lin, Chenhao Ding, Zicong Huang, Cai Zihong, Jia Li, Zhixiang Wang, Xiaofang Li, Xuan Zhou, Bailin He, Wenhao Zhong, Li Xuan, Qifa Liu, Yang Xu, Hongsheng Zhou

Blood (2024) 144 (Supplement 1): 839.

https://doi.org/10.1182/blood-2024-200513

Published: 2024

Journal Articles

Clinical Characteristics and Risk Factors of Chronic Kidney Disease Among Patients with Myeloproliferative Neoplasms

Zicheng Gao, Xuan Zhou, Qiang Wang, Dan Xu, Xiaoli Liu, Na Xu, Qifa Liu

Blood (2024) 144 (Supplement 1): 6643.

https://doi.org/10.1182/blood-2024-207289

Published: 2024

Journal Articles

Safety and Efficacy of Luspatercept for the Treatment of Refractory Anemia in Patients with Myelofibrosis

Ziyu Wen, Xuan Zhou, Bingyu Lin, Xiaoli Liu, Qiang Wang, Na Xu

Blood (2024) 144 (Supplement 1): 6639.

https://doi.org/10.1182/blood-2024-205673

Published: 2024

Journal Articles

Analysis of the Impact of TKI Dose Adjustment Under the Guidance of Blood Concentration Monitoring on the Efficacy, Safety and Quality of Life in Patients with CML

Zherou He, Qing Zhang, Xuan Zhou, Qiang Wang, Xiaoli Liu, Na Xu

Blood (2024) 144 (Supplement 1): 1773.

https://doi.org/10.1182/blood-2024-207302

Published: 2024

Journal Articles

The Efficacy and Safety of Selinexor Plus Ruxolitinib Regimen in Ruxolitinib-Resistant Myelofibrosis: A Retrospective Study

Ziyu Wen, Xuan Zhou, Bingyu Lin, Xiaoli Liu, Qiang Wang, Na Xu

Blood (2024) 144 (Supplement 1): 1803.

https://doi.org/10.1182/blood-2024-205725

Published: 2024

Journal Articles

Flumatinib for the Treatment of Adult Patients with Resistant or Intolerant Chronic-Phase Chronic Myeloid Leukemia: Results from Real-World Data

Xuan Zhou, Na Xu, Ziyu Wen, Hanyin Liang, Dongmei Luo, Hong Chen, Zherou He, Zicheng Gao, Qiang Wang, Dan Xu, Xiaoli Liu, Qifa Liu

Blood (2023) 142 (Supplement 1): 6379.

https://doi.org/10.1182/blood-2023-184643

Published: 2023

Journal Articles

TKI Dose Optimization Based on Therapeutic Drug Monitoring（TDM) with Encouraging Outcomes and Well-Tolerated for Chronic Myeloid Leukaemia Patients

Zherou He, Xuan Zhou, Ziyu Wen, Zicheng Gao, Hong Chen, Qiang Wang, Hanyin Liang, Dongmei Luo, Xiaoli Liu, Na Xu, Qifa Liu

Blood (2023) 142 (Supplement 1): 1807.

https://doi.org/10.1182/blood-2023-182765

Published: 2023

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Outcome of bridging therapy in chimeric antigen receptor T cell treatment for Relapsed/Refractory B-cell non-Hodgkin lymphoma: A retrospective study.

Wstf degradation through nuclear autophagy promotes inflammatory responses in primary myelofibrosis: Implications for XPO1 inhibitor-based therapeutic strategies

Efficacy and safety of peginterferon alfa-2b for chronic myeloid leukemia and essential thrombocythemia during pregnancy

Retrospective analysis of 30mg/kg ATLG in preventing GVHD after haploidentical hematopoietic stem cell transplantation

Novel risk stratification of ph-like ALL cohort receiving CD19-directed CAR-T therapy

Deeper remission achievement and longer leukemia-free survival with inati-cel as consolidation therapy in allogeneic transplant-ineligible adolescent and adult patients with B-ALL

Flumatinib versus nilotinib as first-line therapy for chronic myeloid leukemia in chronic Phase: A propensity score-matched cohort study

Clinical study of single-center PDT-ALL-2016 regimen in the treatment of KMT2A-rearranged acute lymphoblastic leukemia

Real-world efficacy of inaticabtagene autoleucel in adult B-cell acute lymphoblastic leukemia patients with high-risk molecular alterations

Neutrophil count is an independent prognostic indicator in early T-cell precursor lymphoblastic leukemia

Updated Results from a Phase Ⅱ Clinical Trial：Safety and Efficacy of Azacitidine and Chidamide Maintenance after Allogeneic Hematopoietic Stem Cell Transplantation for Patients with High-Risk Acute Myeloid Leukemia

BEAT Chemofree Regimen for Relapsed/Refractory and De Novo T-ALL

Demographic and Clinical Data in 118 Acquired Hemophilia a: Results from a Single Center Study

Tucidinostat Plus Pediatric-Inspired Chemotherapy As First-Line Therapy for Newly Diagnosed ETP-ALL/Lbl: An Open-Label, Single-Arm, Phase 2 Trial

Clinical Characteristics and Risk Factors of Chronic Kidney Disease Among Patients with Myeloproliferative Neoplasms

Safety and Efficacy of Luspatercept for the Treatment of Refractory Anemia in Patients with Myelofibrosis

Analysis of the Impact of TKI Dose Adjustment Under the Guidance of Blood Concentration Monitoring on the Efficacy, Safety and Quality of Life in Patients with CML

The Efficacy and Safety of Selinexor Plus Ruxolitinib Regimen in Ruxolitinib-Resistant Myelofibrosis: A Retrospective Study

Flumatinib for the Treatment of Adult Patients with Resistant or Intolerant Chronic-Phase Chronic Myeloid Leukemia: Results from Real-World Data

TKI Dose Optimization Based on Therapeutic Drug Monitoring（TDM) with Encouraging Outcomes and Well-Tolerated for Chronic Myeloid Leukaemia Patients

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only